Skip to content
Keeping Current cover art

All Episodes

Keeping Current — 632 episodes · page 6 of 7

#
Title
501

ENDO 2021 – New Directions With Weight Loss Concepts of the Future

502

Taking Control of Chronic Spontaneous Urticaria: A Tale of Two Perspectives

503

Advances in Oncogene-Driven Metastatic NSCLC: Focusing on EFGR Exon 20 Insertions and ALK-Positive NSCLC

504

HFpEF Is Arguably the Greatest Unmet Need in Cardiology: The Potential Role of SGLT2 Inhibitors

505

Patient Engagement in MS: What Does This Mean and What Does It Look Like?

506

Neuro-Ophthalmology: What You Need to Know About LHON

507

The Science of MS and Role of S1P Receptor Modulators

508

Emerging Therapies for Chronic Spontaneous Urticaria: Understanding How They Work

509

Molecular Testing – Transplant and Treatment Strategies in AML

510

New Approaches to Ocular Surface Pain

511

Defining NASH As a Metabolic Disease: Can We Afford to Ignore It?

512

Exploring New Targets in Generalized Pustular Psoriasis

513

Challenges and Unmet Needs in Food Allergy: How Big Is the Problem?

514

Fresh Perspective for Patients With nAMD and DME: New Therapies on the Horizon

515

Multiple Sclerosis Education Blitz: Interpreting Recent Advances in B-Cell-Targeted Therapies

516

People Living With HIV: Stifled by Stigma and Impact on Health Outcomes

517

PARP Inhibitor Maintenance in Newly Diagnosed Ovarian Cancer: Key Questions, Answers, and Insights

518

CKD-Associated Pruritus: Impact on Patient Quality of Life

519

The 2021 Heart Failure Treatment Pathway Revolution: What Every Clinician Needs to Know!

520

Dengue Diagnosis: Unique Challenges in a Time of Pandemic

521

Initiating COPD Therapy in Primary Care

522

Development of HF After MI: The Science of Why This Occurs

523

When Interstitial Lung Disease Encounters COVID-19: Clinical Considerations

524

Emerging Treatment Pathways for HFrEF Patients: What Does the Evidence Say?

525

Multidisciplinary Management of Connective Tissue Disease-Associated Interstitial Lung Diseases

526

Current and Emerging Therapies for CKD-Associated Pruritus

527

Update on IL-17 Inhibitors in the Management of Psoriasis

528

HER2 Testing for the Pathologist: Is Your Clinic Up to Date With the Latest Developments?

529

My Life With MS: A Patient Testimony

530

CAR T-Cell Therapy in Real Practice: Optimizing Referral and Treatment of Patients With NHL

531

Latest Data and Perspectives on NASH From the Liver Meeting

532

SGLT2 Inhibitors in Chronic HF Patients: Safety in Clinical Practice

533

The Changing Landscape for HER2+ Advanced Breast Cancer: Clinical Experience With Anti-HER2 Agents

534

Protecting the Diabetic Kidney With Glucose-Lowering Drugs: Essential News for the Nephrologist

535

SGLT2 Inhibitor Data Review: What's New in HFrEF?

536

Managing Patients With Chronic HF Using SGLT2 Inhibitors: Exploring Practical Considerations

537

Understanding the Challenges of Immunosuppression in Kidney Transplant Patients of Childbearing Age

538

Diabetes Insights: The Impact of GLP-1 RAs on Renal Outcomes

539

MS and COVID-19: Rounding Up the Year's Experiences

540

Current and Emerging Therapies for CKD-Associated Pruritus

541

Multifocal Motor Neuropathy: Identifying and Managing a Debilitating Lower Motor Neuron Syndrome

542

An Image Is Worth a Thousand Words: Diagnostic Tips and Tricks in Identifying Fibrotic Lung Disease

543

Transforming Weight Loss Management for Chronic Obesity

544

Combination Therapy in COPD: What Are the Choices?

545

Evolving Paradigms in Myeloma Maintenance

546

Cardiometabolic Risk Control in Diabetes: Latest Insights and Recommendations

547

Adjuvant EGFR TKI Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Current and Future Perspectives

548

New Paradigms for Progressive Fibrosing Interstitial Lung Diseases

549

Exploring New Targets in the IL-23/IL-17 Pathway for Psoriasis

550

The Present and Future of Next-Generation Insulins

551

A Call to Action for Improving Disease Control in Chronic Spontaneous Urticaria: From Guidelines to Clinical Practice

552

SGLT2 Inhibitor Treatment for HFrEF: Demonstrating Safety Beyond the Heart

553

CAR T-Cell Therapy in Lymphoma: Preparation, Communication, and Aftercare

554

IVT Anti-VEGF Therapy: Practical Strategies to Protect Vision and Mitigate Risks

555

Addressing Key Challenges and Unmet Needs in GPP Management

556

A Case-Based Approach to Early Intervention in Schizophrenia: Optimizing Service Provision

557

Cardiometabolic Risk Management With Glucose-Lowering Drugs: Essential News for the Cardiologist

558

Understanding the Immunopathogenesis of CKD-Associated Pruritus

559

Catching and Managing Progressive Fibrosing Interstitial Lung Disease Progression Earlier

560

Latest Insights into CV Risk Reduction with GLP-1 RAs

561

CAR T Cells in B-Cell Lymphoma: Implications of New Data and New Therapy

562

What Are the Effects of SGLT2 Inhibitors In Patients With HFrEF?

563

Optimizing Bronchodilator Therapy in COPD

564

Sin fronteras: perspectivas sobre la optimización del diagnóstico precoz de las infecciones respiratorias y de la meningitis y la encefalitis

565

CD38 Antibodies in Multiple Myeloma: What Next?

566

A Comprehensive Approach to Diagnosis and Treating Patients With Psoriasis and Back Pain

567

Behind the Scenes: Evaluating the Safety of the Expanding Hemophilia A Therapy Armamentarium

568

Clinical Benefits of Fixed-Dose ICS/LABA/LAMA Combination Inhalers in the Management of Asthma

569

Emerging CART-Cell Therapies in Multiple Myeloma: The Evidence and Implications

570

Highlighting New Data in Multiple Myeloma

571

Diabetology and Cardiology in Dialogue -- What is State-of-the-Art for Best Diabetes Care?

572

Risk Assessment in Dyslipidemia For Specialists: An Expert Walkthrough

573

Strategies for Enhancing Patient Adherence to Asthma Therapy

574

Generalized Pustular Psoriasis: What Do You Know?

575

Hyperkalemia and Dialysis: Challenges and Solutions for Improving Management

576

Best Practice Treatment of Relapsed/Refractory Indolent NHL: Case Insights

577

What Have We Learned About Managing Patients With Inflammatory Diseases During the COVID-19 Pandemic?

578

Where Are We Now in Managing Patients With SLE During the COVID-19 Pandemic?

579

CAR T Cells and Hypogammaglobulinemia: What Do We Know and How Do We Manage Patients?

580

CLL and MRD Negativity in Practice: Patients and Practicalities

581

Managing Asthma During the COVID-19 Pandemic: Experts Provide Guidance

582

The Journey Toward Personalized Care in COPD: Where Are We Now?

583

Prevention of Microvascular Complications in Diabetes: Where Do We Stand?

584

Macrovascular Complications in Diabetes: Most Recent Data and Insights

585

The Patient Journey With Dyslipidemia: A Patient's Perspective

586

Principles and Best Practices to Prevent Congenital CMV

587

A Digest of Latest Clinical Data With GLP-1 Receptor Agonists

588

Next-generation Insulins -- What's New?

589

Taking Individualized Neurology Care to the Next Level: The Role of Artificial Intelligence

590

Overcoming Challenges in Ophthalmology: Using Artificial Intelligence to Personalize Care

591

Managing COPD During the COVID-19 Pandemic: Experts Provide Guidance

592

Dyslipidemia Guidelines: Key Takeaways for the Primary Care Physician

593

Familial Hypercholesterolemia: What Every Primary Care Physician Needs to Know

594

Exploring Analgesic Options for Dental Pain

595

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): What Clinicians Need to Know About This Condition

596

Hypogammaglobulinemia in Patients With Hematologic Malignancies: Practical Considerations for Diagnosis and Management

597

The COVID-19 Pandemic: What Every Clinician Needs to Know, Now

598

Head-to-Head Studies in PsA: Understanding the Outcomes

599

Recent Developments in the Management of Patients with Moderate to Severe Asthma

600

GLP-1 Receptor Agonists for Primary Care: What's New? – Quick Questions – Immediate Insights